Healthcare
Live Price
Offline$10.75
-4.27% today
1Y Change
+89.47%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
P3 Health Partners Inc. (PIII) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $10.75 and up 89.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -2.8%, EPS growth of +3.3%, a dividend yield of 0.0%. What stands out right now is revenue -2.8%, EPS +3.3%, free cash flow +17.2% with operating margin -18.5% and ROIC -172.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PIII price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PIII
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PIII Max Drawdown
-85.08%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PIII and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$637.4M
-39.3% YoY
FY Net Income
-$156.5M
+42.1% YoY
Free Cash Flow
-$69.9M
+45.5% YoY
Revenue Growth
-2.8%
EPS Growth
+3.3%
Gross Margin
18.0%
Net Margin
-10.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.5B | 1.5B | 1.3B | 1.0B | 637M |
| Gross Profit | -144M | 1.5B | 1.3B | 1.0B | -31M |
| Operating Income | -270M | -321M | -168M | -1.6B | -188M |
| EBITDA | -186M | -198M | -81M | -1.5B | -185M |
| Net Income | -148M | -136M | -58M | -270M | -156M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25M | 39M | 36M | 18M | 140M |
| Total Assets | 657M | 783M | 861M | 877M | 2.4B |
| Total Liabilities | 797M | 634M | 427M | 354M | 300M |
| Shareholder Equity | -155M | 76M | 142M | 6M | 274M |
| Total Debt | 287M | 166M | 125M | 108M | 92M |
| Net Debt | 262M | 127M | 88M | 89M | -48M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
66M
+47.3% YoY
Capital Expenditures
3M
-52.8% YoY
Free Cash Flow
70M
+45.5% YoY
Key ratios
Gross Margin
18.0%
Operating Margin
-18.5%
Net Margin
-10.1%
ROE
893.8%
Debt / Equity
-0.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.